Selected Publications

Chirra M, Elliott A, Shaikh H, McGrath J, El-Gamal D, Karnezis AN, Abdulla FR, Ikpeazu C, Leddon J, Sukari A, Zandberg DP, Johnson JM, Sun L, Wise-Draper TM.: Molecular Profiling and Real-World Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer. Clin Cancer Res Jan 2026.

Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ.: Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res Jan 2026.

Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME.: Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC). Lung Cancer 213: 108936, Jan 2026.

Yegya-Raman N, Ko K, Han IS, Mitchell JD, Zou W, Ohri N, Jabbour SK, Mak RH, Robinson C, Levin WP, Barrett L, Xia C, Berlin E, Bravo P, Carli MD, Cohen R, Hutton S, Keltz J, Wang J, Fasan O, Nagda SN, Seo A, Smith AM, Sun L, Soike M, Kole AJ, Walls G, Feigenberg SJ, Ky B.: Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study. Clin Transl Radiat Oncol 56: 101070, Nov 2025.

Gobillot TA, Weinstein G, Cao A, Lee JJ, Brody RM, Basu D, O'Malley BW Jr, Farwell DG, Cannady S, Lin A, Lukens J, Gentile M, Newman JG, Chalian AA, Sun L, Lakshmipathy D, Cohen RB, Rasskeh CH, Rajasekaran K.: Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery. Laryngoscope Aug 2025.

Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D.: Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer. J Natl Cancer Inst 117: 1366-1376, Jul 2025.

Liu KL, Watts A, Grady CB, Liu G, Patel D, Balaratnam K, Liu SV, Montenegro GB, Nie Y, Nieva J, Herrmann A, Marrone K, Lam V, Sun F, Dowell J, Schwartzman W, Velcheti V, Fankuchen O, Ullah T, Villaruz L, Nguyen M, Weiss J, Patel S, Miller K, Iams W, Chandrasekhara K, Tompkins W, Patil T, Aisner D, Camidge DR, Hwang WT, Sun L, Marmarelis ME.: Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC. JTO Clin Res Rep 6: 100876, Jul 2025.

Sun L, Marmarelis ME, Aggarwal C.: Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer. J Clin Oncol 43(13), May 2025.

Cohen RB, Jimeno A, Hreno J, Sun L, Wallén-Öhman M, Millrud CR, Sanfridson A, Garcia-Ribas I.: Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors. Invest New Drugs May 2025.

Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME.: Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer 203(108551), May 2025.